Amphiphilic irinotecan-melampomagnolide B conjugate nanoparticles for cancer chemotherapy.
Journal
RSC advances
ISSN: 2046-2069
Titre abrégé: RSC Adv
Pays: England
ID NLM: 101581657
Informations de publication
Date de publication:
27 Feb 2020
27 Feb 2020
Historique:
received:
31
01
2020
accepted:
17
02
2020
entrez:
2
5
2022
pubmed:
2
3
2020
medline:
2
3
2020
Statut:
epublish
Résumé
Melampomagnolide B (MMB) is a natural sesquiterpene lactone product structurally related to parthenolide (PTL). Although MMB has been widely used to treat various types of cancers, such as glioma, leukemia and colon cancer, the effective delivery of MMB to cancer cells remains a challenge. An amphiphilic drug-drug conjugate (ADDC) strategy has been proposed and developed as a promising drug self-delivery system for cancer therapy because of its simple preparation, carrier-free nature, and high therapeutic activity. Herein, we present a new ADDC, which is synthesized by linking the hydrophilic anticancer drug irinotecan (Ir) and the hydrophobic anticancer drug MMB through a carbonate bond. The obtained amphiphilic irinotecan-melampomagnolide B conjugate (Ir-C-MMB) can self-assemble in water into stable nanoparticles with an average diameter of around 122.1 nm. After cellular uptake, the carbonate bond between the hydrophilic drug and hydrophobic drug can be cleaved to release free Ir and MMB under acidic conditions, which exhibit a synergistic effect in tumor cells. MTT results reveal that the Ir-C-MMB nanoparticles can effectively inhibit proliferation of cancer cells. The apoptosis data indicate that the apoptosis rate of cells treated with Ir-C-MMB nanoparticles is about 50% within 24 h, which is much higher than that of free Ir or MMB. Our results suggest that this ADDC strategy could be used as a drug delivery platform for MMB and its derivatives, and that it offers effective synergistic therapeutic efficacy.
Identifiants
pubmed: 35496516
doi: 10.1039/d0ra00912a
pii: d0ra00912a
pmc: PMC9050120
doi:
Types de publication
Journal Article
Langues
eng
Pagination
8958-8966Informations de copyright
This journal is © The Royal Society of Chemistry.
Déclaration de conflit d'intérêts
There are no conflicts to declare.
Références
Breast Cancer Res Treat. 2008 Oct;111(3):419-27
pubmed: 17965935
J Cell Biochem. 2012 Apr;113(4):1282-91
pubmed: 22109788
Bioorg Med Chem. 2017 Jul 15;25(14):3694-3705
pubmed: 28545815
Bioorg Med Chem. 2011 Feb 15;19(4):1515-9
pubmed: 21273084
Bioorg Med Chem Lett. 2014 Aug 1;24(15):3499-502
pubmed: 24928404
J Am Chem Soc. 2018 Jan 31;140(4):1235-1238
pubmed: 29332390
Mol Cancer Ther. 2005 Jun;4(6):1004-12
pubmed: 15956258
Theranostics. 2019 Aug 12;9(20):5755-5768
pubmed: 31534517
J Biol Chem. 1998 Jan 16;273(3):1288-97
pubmed: 9430659
Biochem Pharmacol. 2011 Feb 1;81(3):412-24
pubmed: 21040711
J Am Chem Soc. 2019 May 22;141(20):8158-8170
pubmed: 31053030
Biochemistry. 1978 Nov 14;17(23):5026-31
pubmed: 718871
J Am Chem Soc. 2018 Dec 26;140(51):17956-17961
pubmed: 30525544
Nat Prod Rep. 1995 Jun;12(3):271-6
pubmed: 7792073
J Am Chem Soc. 2007 Dec 12;129(49):15096-7
pubmed: 17999499
Bioconjug Chem. 2015 Dec 16;26(12):2497-506
pubmed: 26497258
J Nat Prod. 2014 Mar 28;77(3):703-23
pubmed: 24499205
Bioconjug Chem. 2016 Jul 20;27(7):1564-8
pubmed: 27206493
J Am Chem Soc. 2014 Aug 20;136(33):11748-56
pubmed: 25078892
J Biol Chem. 2002 Oct 11;277(41):38954-64
pubmed: 12151389
Pharm Res. 1987 Dec;4(6):509-14
pubmed: 2907784
PLoS One. 2009 Dec 02;4(12):e8115
pubmed: 19956548
Chem Rev. 2016 Feb 24;116(4):2602-63
pubmed: 26854975
Bioconjug Chem. 2016 Nov 16;27(11):2722-2733
pubmed: 27723981
Mol Cancer Res. 2009 Jul;7(7):1139-49
pubmed: 19584264
J Biol Chem. 2001 Oct 26;276(43):39713-20
pubmed: 11500489
Mol Pharm. 2015 Jul 6;12(7):2328-36
pubmed: 25996874
Cancer Res. 2005 Apr 1;65(7):2804-14
pubmed: 15805281
J Control Release. 2017 Nov 28;266:36-46
pubmed: 28893609
Chem Rev. 2015 Oct 14;115(19):10967-1011
pubmed: 26463640
Anticancer Drugs. 2012 Oct;23(9):883-96
pubmed: 22797176
Antiviral Res. 1995 May;27(1-2):99-109
pubmed: 7486962
Prostate. 2009 Jun 1;69(8):827-37
pubmed: 19204913
Nat Nanotechnol. 2010 Jun;5(6):465-72
pubmed: 20383126
Mol Cancer Ther. 2005 Apr;4(4):587-94
pubmed: 15827332
Nat Nanotechnol. 2019 Aug;14(8):799-809
pubmed: 31263194
Angew Chem Int Ed Engl. 2009;48(10):1807-9
pubmed: 19173270
Apoptosis. 2006 Dec;11(12):2225-35
pubmed: 17051330
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593